Mechanisms of Resistance to First-Line Osimertinib in Hispanic Patients With EGFR Mutant Non-Small Cell Lung Cancer (FRESTON-CLICaP).

doi:10.1016/j.cllc.2022.06.001

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Mechanisms of Resistance to First-Line Osimertinib in Hispanic Patients With EGFR Mutant Non-Small Cell Lung Cancer (FRESTON-CLICaP).

Clinical lung cancer - 1 Sept 2022

Cardona Andrés F, Ruiz-Patiño Alejandro, Recondo Gonzalo, Martín Claudio, Raez Luis, Samtani Suraj, Minata José Nicolas, Blaquier Juan Bautista, Enrico Diego, Burotto Mauricio, Ordóñez-Reyes Camila, Chamorro Diego F, Garcia-Robledo Juan Esteban, Corrales Luis, Zatarain-Barrón Zyanya Lucia, Más Luis, Sotelo Carolina, Ricaurte Luisa, Santoyo Nicolas, Cuello Mauricio, Mejía Sergio, Jaller Elvira, Vargas Carlos, Carranza Hernán, Otero Jorge, Rodríguez July, Archila Pilar, Bermudez Maritza, Gamez Tatiana, Cordeiro de Lima Vladmir, Freitas Helano, Russo Alessandro, Polo Carolina, Malapelle Umberto, Perez Diego de Miguel, Rolfo Christian, Viola Lucia, Rosell Rafael, Arrieta Oscar

Abstract excerpt

INTRODUCTION: Osimertinib is a third generation EGFR-TKI inhibitor approved in the first-line setting for patients with advanced non-small cell lung cancer (NSCLC). Additionally, it represents the treatment of choice in patients who present with T790M mutations and evidence of relapse of the disease. Effectiveness and safety of this drug have been studied in multiple clinical trials and observational studies,...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Acrylamides

Share to Aniline Compounds

Share to Drug Resistance, Neoplasm

Share to Hispanic or Latino

Share to Indoles

Share to Liver Neoplasms

Share to Neoplasm Recurrence, Local

Share to Pyrimidines

Source

Open in PubMed

Identifiers

PMID: 35798634
DOI: 10.1016/j.cllc.2022.06.001

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 3 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Mechanisms of Resistance to First-Line Osimertinib in Hispanic Patients With EGFR Mutant Non-Small Cell Lung Cancer (FRESTON-CLICaP).PMID 35798634Read ↗

The study of primary and acquired resistance to first-line osimertinib to improve the outcome of EGFR-mutated advanced Non-small cell lung cancer patients: the challenge is open for new therapeutic strategies.Semantic proximity Read ↗

Genomic Landscape of Primary Resistance to Osimertinib Among Hispanic Patients with EGFR-Mutant Non-Small Cell Lung Cancer (NSCLC): Results of an Observational Longitudinal Cohort Study.Semantic proximity Read ↗

Mechanisms of resistance to osimertinibSemantic proximity Read ↗

A consensus on the role of osimertinib in non-small cell lung cancer from the AME Lung Cancer Collaborative GroupSemantic proximity Read ↗

Therapeutic approaches for T790M mutation positive non-small-cell lung cancer.Semantic proximity Read ↗

Histomolecular Resistance Mechanisms to First-Line Osimertinib in EGFR-Mutated Advanced Non-Small Cell Lung Cancer: A Multicentric Retrospective French Study.Semantic proximity Read ↗

Osimertinib for the treatment of non-small cell lung cancer.Semantic proximity Read ↗

Patterns of progression on first line osimertinib in patients with EGFR mutation-positive advanced non-small cell lung cancer (NSCLC): A Swiss cohort study.Semantic proximity Read ↗

Acquired Resistance to Osimertinib in EGFR-Mutated Non-Small Cell Lung Cancer: How Do We Overcome It?Semantic proximity Read ↗

Post-Progression Survival in Secondary EGFR T790M-Mutated Non-Small-Cell Lung Cancer Patients With and Without Osimertinib After Failure of a Previous EGFR TKI.Semantic proximity Read ↗

An overview of osimertinib as a treatment of non-small cell lung cancer (NSCLC): an update.Semantic proximity Read ↗

Acquired Resistance to Erlotinib in EGFR Mutation-Positive Lung Adenocarcinoma among Hispanics (CLICaP).Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.